We are live on ! Find out more
HBIO icon

Harvard Bioscience

84 hedge funds and large institutions have $129M invested in Harvard Bioscience in 2015 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

12% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 25

12% more capital invested

Capital invested by funds: $116M → $129M (+$13.3M)

6% more funds holding

Funds holding: 7984 (+5)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $54K

Holders
84
Holders Change
+5
Holders Change %
+6.33%
% of All Funds
2.26%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
18
Increased
28
Reduced
25
Closed
13
Calls
Puts
$54K
Net Calls
-$54K
Net Calls Change
-$61K
Name Holding Trade Value Shares
Change
Change in
Stake
GIP
26
Granite Investment Partners
California
$1.26M -$319K -5,602 -20%
TA
27
Teton Advisors
New York
$1.21M +$68.3K +1,200 +6%
BCM
28
Bridgeway Capital Management
Texas
$1.15M
CCM
29
Cadence Capital Management
Massachusetts
$1.11M -$53.8K -945 -5%
CAM
30
ClariVest Asset Management
California
$1.03M -$8.48K -149 -0.8%
GC
31
Globeflex Capital
California
$1.01M
WIC
32
Woodmont Investment Counsel
Tennessee
$922K -$276K -4,844 -23%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$857K +$74.8K +1,314 +10%
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$793K
Bank of New York Mellon
35
Bank of New York Mellon
New York
$787K +$548K +9,627 +230%
PCMI
36
Paradigm Capital Management Inc
New York
$767K +$766K +13,460 New
PM
37
Penbrook Management
New York
$741K -$1.62M -28,510 -69%
Axa
38
Axa
France
$715K +$77.3K +1,359 +12%
WCM
39
Wedge Capital Management
North Carolina
$706K -$3.98K -70 -0.6%
BIM
40
BlackRock Investment Management
Delaware
$654K +$623K +10,955 +2,087%
TCIM
41
TIAA CREF Investment Management
New York
$653K +$652K +11,453 New
SO
42
STRS Ohio
Ohio
$649K +$648K +11,390 New
TC
43
TFS Capital
Pennsylvania
$562K +$561K +9,865 New
Northern Trust
44
Northern Trust
Illinois
$537K +$147K +2,584 +38%
Wells Fargo
45
Wells Fargo
California
$472K +$301K +5,281 +176%
PAM
46
Panagora Asset Management
Massachusetts
$418K +$407K +7,147 +3,703%
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$348K +$348K +6,110 New
Charles Schwab
48
Charles Schwab
California
$343K +$232K +4,073 +211%
SB
49
Suntrust Banks
Georgia
$341K +$341K +5,985 New
BG
50
BlackRock Group
United Kingdom
$324K -$538K -9,448 -62%

HBIO Hedge Fund Activity: Q2 2015 in Review

84 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2015, worth a combined $129M — up 12% from $116M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new HBIO positions and 13 closed out — a net gain of 5 holders — while 28 added to existing stakes and 25 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $4.42M. The largest seller was Penbrook Management, cutting an estimated $1.62M.

  • 84 institutional investors held Harvard Bioscience (HBIO) as of Q2 2015, up from 79 in Q1 2015.
  • Funds reported $129M of Harvard Bioscience stock for Q2 2015, up 12% quarter-over-quarter.
  • 18 funds opened new Harvard Bioscience positions in Q2 2015 and 13 closed out, a net change of +5 holders.
  • The largest Harvard Bioscience buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $4.42M added.
  • The largest Harvard Bioscience seller in Q2 2015 was Penbrook Management, an estimated $1.62M sold.

Based on aggregated 13F filings for Q2 2015.